NICE Accepts Fewer Side Effects In Recommending Sanofi-Aventis's Multaq
This article was originally published in The Pink Sheet Daily
Executive Summary
Second draft appraisal of Multaq recommends use in atrial fibrillation, even though the drug is less effective than other anti-arrhythmics
You may also be interested in...
NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq
NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.
NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq
NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.
FDA Social Media Group Reviewing Its First iPhone App As DTC Marketing Tool, But It's Not The First To Be Released
FDA has started wading into the iPhone business, at least to help determine how drug companies can use the App Store. FDA's social media working group is reviewing its first submission for an iPhone app as a direct-to-consumer marketing tool, Division of Drug Marketing, Advertising and Communications special assistant Jean-Ah Kang told the DTC National Conference April 9